Sales Executive
About the job
- A bachelor's degree in Business, Sales, Logistics, Supply Chain, Life Sciences, Healthcare, or a related field, or equivalent professional experience.
- Experience in business development, sales, account management, or a related commercial role.
- Demonstrated success in generating new business and achieving sales objectives.
- Experience managing customer relationships and developing existing accounts.
- Ability to analyze commercial data, identify trends, and translate insights into business actions.
- Ability to build relationships with senior stakeholders and decision-makers.
- Willingness and ability to travel extensively throughout France.
- Valid driver's license.
- Fluent French and professional English, both written and spoken.
- Strong prospecting, business development, and lead generation capabilities.
- Communication, presentation, negotiation, and relationship-management skills.
- Commercial awareness and a customer-focused mindset.
- Ability to identify, develop, and convert new business opportunities.
- Ability to combine strategic thinking with hands-on execution.
- Analytical skills, including interpreting data, identifying opportunities, and supporting business decision-making.
- Ability to work independently, take ownership, and manage multiple priorities in a dynamic environment.
- Organizational, planning, and time-management skills.
- Knowledge of CRM systems and Microsoft Office applications.
- Identify, acquire, and develop new business opportunities in the pharmaceutical, biotechnology, healthcare, clinical research, and related sectors.
- Develop and execute territory sales plans to increase market presence and achieve revenue growth objectives.
- Build and maintain a pipeline through prospecting, networking, market research, referrals, and industry engagement.
- Conduct customer presentations, solution-based discussions, and commercial negotiations to secure new business.
- Represent World Courier at customer meetings, industry events, conferences, and networking activities.
- Identify new opportunities, market segments, and approaches to grow business within the assigned territory.
- Manage and grow an assigned portfolio of existing customers.
- Build long-term relationships with key stakeholders and decision-makers.
- Identify cross-selling and upselling opportunities across the World Courier service portfolio.
- Maintain customer satisfaction and address customer needs to support retention and growth.
- Analyze sales performance, pipeline activity, market trends, customer requirements, and competitor activities to identify growth opportunities and define territory priorities.
- Translate data and market insights into actionable business strategies and growth plans.
- Develop and execute strategic initiatives to maximize territory performance and achieve commercial objectives.
- Gather and share market insights to support business strategy and service development.
- Maintain awareness of industry regulations, quality standards, and logistics requirements affecting customers.
- Collaborate with Operations, Customer Service, Quality, and other internal teams to develop and implement customer solutions.
- Support tender processes, proposals, pricing activities, contract discussions, and customer onboarding.
- Maintain accurate customer information, sales activity records, forecasts, and pipeline updates within CRM systems.
- Work across functions to ensure successful execution of commercial strategies and customer initiatives.
- Experience working with pharmaceutical, biotechnology, healthcare, clinical research, or specialty logistics customers.
- Knowledge of GDP, GxP, clinical trial logistics, temperature-controlled transportation, or other regulated logistics environments.
- Understanding of healthcare and life sciences supply chains.
- Established professional network within the healthcare, pharmaceutical, biotechnology, or life sciences sectors.
About the company
Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.
Company Size
10,001+
Company Stage
IPO
Headquarters
Conshohocken, Pennsylvania
Founded
2001
Get referred to Cencora
See people who can refer or advise you
Simplify's Take
What believers are saying
- Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
- Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
- Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.
What critics are saying
- Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
- Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
- Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.
What makes Cencora unique
- Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
- Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
- Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Company News
Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.
Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.
Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.
Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.
Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.